Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prolight Diagnostics ABNGM:PRLD +2.29%31 EV-to-OCF is -4.79 as of Aug. 02, 2026. GuruFocus rates NGM:PRLD with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 853 Medical Devices & Instruments companies, Prolight Diagnostics AB ranks better than 73.86% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Prolight Diagnostics AB's Enterprise Value is kr198.34 Mil.
Prolight Diagnostics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was kr-41.44 Mil. Therefore, Prolight Diagnostics AB's EV-to-OCF for today is -4.79.
The historical rank and industry rank for Prolight Diagnostics AB's EV-to-OCF or its related term are showing as below:
NGM:PRLD'
s EV-to-OCF Range Over the Past 10 Years
Min: -5.01 Med: 0 Max: -5.01
Current: -5.01
During the past 10 years, the highest EV-to-OCF of Prolight Diagnostics AB was -5.01. The lowest was -5.01. And the median was .
NGM:PRLD's EV-to-OCF is ranked better than 73.86% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.9
vs NGM:PRLD: -5.01
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prolight Diagnostics AB (NGM:PRLD) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prolight Diagnostics AB's PE Ratio (TTM) for today is calculated as:
Prolight Diagnostics AB's share price for today is kr17.90.
Prolight Diagnostics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-4.870.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Prolight Diagnostics AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prolight Diagnostics AB EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prolight Diagnostics AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Prolight Diagnostics AB's EV-to-OCF falls into.
Prolight Diagnostics AB's current Enterprise Value is kr198.34 Mil.
Prolight Diagnostics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-41.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prolight Diagnostics AB (NGM:PRLD) has a EV-to-OCF of -4.79 as of Aug. 02, 2026. According to the industry distribution chart, Prolight Diagnostics AB ranks #223 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 26.1%.
Is Prolight Diagnostics AB's EV-to-OCF too high?
Prolight Diagnostics AB's current EV-to-OCF is -4.79. Based on the distribution chart, Prolight Diagnostics AB ranks #223 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Prolight Diagnostics AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Prolight Diagnostics AB's EV-to-OCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prolight Diagnostics AB ranks #223 out of 853 companies for EV-to-OCF. This puts Prolight Diagnostics AB in the upper half of its industry. The industry median EV-to-OCF is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.90, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prolight Diagnostics AB's current EV-to-OCF is -4.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prolight Diagnostics AB stock overvalued right now?
Prolight Diagnostics AB (NGM:PRLD) has a current EV-to-OCF of -4.79. The current EV-to-OCF is -4.79. Prolight Diagnostics AB's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Prolight Diagnostics AB (NGM:PRLD), the current EV-to-OCF is -4.79 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
31GF Score
Get the complete analysis for NGM:PRLD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:PRLD has been successfully added to your 
